(Reuters) -The UK’s drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare’s HIV drug, enabling access to the preventive medicine via the state health system in England and Wales, the GSK unit said on Friday.

The country’s drug regulator had approved ViiV’s injection, Apretude, last year for prevention of HIV-1 in adults and young people who weigh at least 35 kilograms and are at high risk of acquiring the infection.

A positive recommendation from the National Institute for Health and Care Excellence, or NICE, solidifies the final guidance related to Apretude for National Health Service, ViiV said.

It also allows the drug to be routinely funded and enables access through NHS. Pending any appeals, the drug will be available to eligible people in Wales w

See Full Page